Drug Trial Radar · NCT06079359
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
May 14, 2024
Primary completion
Jan 6, 2026
Study completion Aug 24, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.
Conditions
- Hypophosphatasia
Interventions
ALXN1850Drug
Participants will receive a ALXN1850 via subcutaneous (SC) injection.
PlaceboDrug
Participants will receive placebo via SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Global Impression of Change (RGI-C) Score at the end of the Randomized Evaluation Period (Day 169)Time frame: Day 169
Locations
32 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Baltimore, Maryland
Research Site
Kansas City, Missouri
Research Site
Durham, North Carolina
Research Site
Nedlands, Australia
Research Site
Parkville, Australia
Research Site
Brussels, Belgium
Research Site
Brasília, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Recife, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Winnepeg, Manitoba, Canada
Research Site
Beijing, China
Research Site
Guangzhou, China
Research Site
Shanghai, China
Research Site
Shenzhen, China
Research Site
Helsinki, Finland
Research Site
Ashkelon, Israel
Research Site
Chihuahua City, Mexico
Research Site
Lodz, Poland
Research Site
Bucharest, Romania
Research Site
Madrid, Spain
Research Site
Vitoria-Gasteiz, Spain
Research Site
Stockholm, Sweden
Research Site
Taipei, Taiwan
Research Site
Ankara, Turkey (Türkiye)
Research Site
Bursa, Turkey (Türkiye)
Research Site
Erzurum, Turkey (Türkiye)
Research Site
Istanbul, Turkey (Türkiye)
Research Site
Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.